Thanks for sharing Tina. It looks like the AQX-1125 product is to reduce the inflammatory response. That doesn't target the cause, so looks like a long-term, dependent medication. That's good for Aquinox Pharma.
I hope Prof Marshall and Dr Volikova find the CAUSE of the inflammation, so we can be cured and not saddled with another 'management' drug that keeps this vulnerable group of people dependent on Big Pharma so we can help line their pockets.